ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Akero Announces Dosing of First Patient in NASH Study
July 04, 2019Akero Therapeutics announced the dosing of the first patient in its Phase 2a clinical study of AKR-001, a novel FGF21 analog, for the treatment of NASH (the BALANCED study). -
RedHill Biopharma Announces First Dosing in RHB-105 Supportive PK Studies Ahead of Confirmatory Phas
January 11, 2017The first group of subjects have been dosed in a single-dose three-way crossover pharmacokinetic (PK) study with RHB-105 versus the active comparators in the confirmatory Phase III study and in a food-effect study with RHB-105 in healthy volunteers
Pharma Sources Insight January 2025
